- Home
- DRUG vs CYBN Comparison
DRUG vs CYBN Comparison
Compare DRUG & CYBN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRUG
- CYBN
- Stock Information
- Founded
- DRUG 2019
- CYBN 2019
- Country
- DRUG United States
- CYBN Canada
- Employees
- DRUG N/A
- CYBN N/A
- Industry
- DRUG Pharmaceuticals and Biotechnology
- CYBN Pharmaceuticals and Biotechnology
- Sector
- DRUG Health Care
- CYBN Health Care
- Exchange
- DRUG Nasdaq
- CYBN Nasdaq
- Market Cap
- DRUG 210.7M
- CYBN 229.8M
- IPO Year
- DRUG N/A
- CYBN N/A
- Fundamental
- Price
- DRUG $32.38
- CYBN $10.19
- Analyst Decision
- DRUG
- CYBN Strong Buy
- Analyst Count
- DRUG 0
- CYBN 3
- Target Price
- DRUG N/A
- CYBN $138.00
- AVG Volume (30 Days)
- DRUG 382.4K
- CYBN 559.2K
- Earning Date
- DRUG 11-26-2024
- CYBN 11-13-2024
- Dividend Yield
- DRUG N/A
- CYBN N/A
- EPS Growth
- DRUG N/A
- CYBN N/A
- EPS
- DRUG N/A
- CYBN N/A
- Revenue
- DRUG N/A
- CYBN N/A
- Revenue This Year
- DRUG N/A
- CYBN N/A
- Revenue Next Year
- DRUG N/A
- CYBN N/A
- P/E Ratio
- DRUG N/A
- CYBN N/A
- Revenue Growth
- DRUG N/A
- CYBN N/A
- 52 Week Low
- DRUG $0.93
- CYBN $6.50
- 52 Week High
- DRUG $79.02
- CYBN $21.66
- Technical
- Relative Strength Index (RSI)
- DRUG 43.69
- CYBN 47.03
- Support Level
- DRUG $36.02
- CYBN $10.36
- Resistance Level
- DRUG $44.70
- CYBN $13.88
- Average True Range (ATR)
- DRUG 5.79
- CYBN 1.32
- MACD
- DRUG -3.22
- CYBN -0.08
- Stochastic Oscillator
- DRUG 6.26
- CYBN 8.40
About DRUG Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
About CYBN Cybin Inc.
Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The company is focused on advancing psychedelic-based therapies, delivery mechanisms, novel compounds, and protocols as potential treatments for various psychiatric and neurological conditions.